Vas Narasimhan

Chief Executive Officer - Novartis AG

3h ago
Novartis returns to growth in Q2 as new cancer drugs offset 50% Entresto slump
Newer drugs Kisqali and Pluvicto drove a 36% revenue surge to nearly $7 billion, helping the Swiss pharma group post $14.4 billion in sales and stable core profit of $5.94 billion.